We are international
Donate
TEXT SIZE   
   back

The International Myeloma Foundation says Pomalidomide Approval in Europe Addresses Critical Need for More Treatment Options for Patients

--Pomalidomide (IMNOVID® in Europe; POMALYST® in the U.S.) Is Approved for Patients in Europe and the U.S. Who Have Had Multiple Prior Treatments--

--IMF Calls for Rapid Reimbursement Approvals throughout the EU--

08.11.13

Be the first to comment

 related articles